Before 16 federal appellate judges for the Fifth Circuit U.S. Court of Appeals, Steve Shadowen argued today an issue of first impression: whether the Constitution's fundamental right to live extends to a non-citizen standing in Mexico who was unjustifiably shot and killed by a U.S. border patrol agent. "If there ever was a case that calls out for practical and functional judicial review of executive U.S. conduct, this is that case," Mr. Shadowen argued. "There is no legal black hole on the Border.”
WASHINGTON DC - December 3, 2013 - The American Antitrust Institute (AAI) held its first annual Antitrust Enforcement Awards tonight, honoring litigation achievements in economics and private law practice.
Law360 reports on Hilliard & Shadowen's victory over defendants'
statute of limitations motion for summary judgment in Nexium case:
A Massachusetts federal judge on Wednesday rejected AstraZeneca PLC and Ranbaxy Inc.'s bid to dismiss as time-barred certain claims in multidistrict litigation alleging the companies violated antitrust laws by agreeing to delay entry of a generic version of AstraZeneca’s heartburn drug Nexium. U.S. District Judge William G. Young denied AstraZeneca and generics manufacturer Ranbaxy's motion for partial summary judgment on claims relating to Ranbaxy's alleged exclusion from the market because of a settlement agreement between the two companies, saying the plaintiffs have presented evidence supporting their position that the statute of limitations on those claims did not start to run when the agreement was executed in April 2008.
The American Antitrust Institute has announced its selection of leading legal practitioners and economists to be recognized at the AAI 2013 Antitrust Enforcement Awards. Steve Shadowen of Hilliard & Shadowen has been selected as an Outstanding Antitrust Litigation Achievement in Private Law Practice Finalist.
Law360 reports on Hilliard & Shadowen's victory in class certification battle in Nexium case:
Massachusetts federal judge certified a class of Nexium end-buyers on
Thursday who accused AstraZeneca PLC and others of violating antitrust
laws by delaying a generic version of AstraZeneca’s heartburn drug,
ruling the class met adequacy and predominance requirements. In
the multidistrict litigation, the judge certified a damages class
consisting of an unidentified number of individual consumers,
third-party payors, union plan sponsors and insurance companies that
bought or provided reimbursements for Nexium in more than 20 states and
the District of Columbia. The class period will last from Apr. 14, 2008,
until the alleged anticompetitve effects of the companies' unlawful
conduct end, the judge said. The Nexium buyers allege that
AstraZeneca established market power and used that power to harm
competition when it entered into agreements with generic-drug makers
Ranbaxy Inc., Teva Pharmaceutical Industries Ltd. and Dr. Reddy’s
(Reuters) – When the U.S. Supreme Court issues its ruling on payments by brand-name drug companies to generic rivals to keep cheaper products off the market, many experts expect a complex analysis to emerge.